vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and NPK International Inc. (NPKI). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $75.2M, roughly 1.2× NPK International Inc.). On growth, NPK International Inc. posted the faster year-over-year revenue change (30.7% vs 17.7%). NPK International Inc. produced more free cash flow last quarter ($5.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 23.9%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
IOVA vs NPKI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $75.2M |
| Net Profit | — | — |
| Gross Margin | 67.4% | 37.7% |
| Operating Margin | -84.7% | 16.7% |
| Net Margin | — | — |
| Revenue YoY | 17.7% | 30.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $75.2M | ||
| Q3 25 | $67.5M | $68.8M | ||
| Q2 25 | $60.0M | $68.2M | ||
| Q1 25 | $49.3M | $64.8M | ||
| Q4 24 | $73.7M | $57.5M | ||
| Q3 24 | $58.6M | $44.2M | ||
| Q2 24 | $31.1M | $66.8M | ||
| Q1 24 | $715.0K | $49.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $5.7M | ||
| Q2 25 | $-111.7M | $8.7M | ||
| Q1 25 | $-116.2M | $10.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $-174.3M | ||
| Q2 24 | $-97.1M | $8.0M | ||
| Q1 24 | $-113.0M | $7.3M |
| Q4 25 | 67.4% | 37.7% | ||
| Q3 25 | 43.0% | 31.9% | ||
| Q2 25 | 5.5% | 36.9% | ||
| Q1 25 | -0.8% | 39.0% | ||
| Q4 24 | 68.7% | 39.2% | ||
| Q3 24 | 46.2% | 27.5% | ||
| Q2 24 | -0.8% | 37.2% | ||
| Q1 24 | — | 36.0% |
| Q4 25 | -84.7% | 16.7% | ||
| Q3 25 | -140.7% | 13.2% | ||
| Q2 25 | -189.8% | 17.0% | ||
| Q1 25 | -245.8% | 20.9% | ||
| Q4 24 | -117.5% | 20.2% | ||
| Q3 24 | -152.1% | 2.8% | ||
| Q2 24 | -327.6% | 18.7% | ||
| Q1 24 | -16464.6% | 14.2% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | 8.2% | ||
| Q2 25 | -186.2% | 12.7% | ||
| Q1 25 | -235.5% | 15.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | -394.3% | ||
| Q2 24 | -312.2% | 12.0% | ||
| Q1 24 | -15800.8% | 14.9% |
| Q4 25 | — | $0.17 | ||
| Q3 25 | — | $0.07 | ||
| Q2 25 | $-0.33 | $0.10 | ||
| Q1 25 | $-0.36 | $0.11 | ||
| Q4 24 | $-0.24 | $0.10 | ||
| Q3 24 | $-0.28 | $-1.99 | ||
| Q2 24 | $-0.34 | $0.09 | ||
| Q1 24 | $-0.42 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $5.1M |
| Total DebtLower is stronger | — | $16.9M |
| Stockholders' EquityBook value | $698.6M | $351.2M |
| Total Assets | $913.2M | $441.8M |
| Debt / EquityLower = less leverage | — | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $5.1M | ||
| Q3 25 | $300.8M | $35.6M | ||
| Q2 25 | $301.2M | $26.0M | ||
| Q1 25 | $359.7M | $20.8M | ||
| Q4 24 | $323.8M | $17.8M | ||
| Q3 24 | $397.5M | $42.9M | ||
| Q2 24 | $412.5M | $35.1M | ||
| Q1 24 | $356.2M | $37.7M |
| Q4 25 | — | $16.9M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | — | $7.7M | ||
| Q3 24 | — | $14.0M | ||
| Q2 24 | — | $58.0M | ||
| Q1 24 | — | $77.4M |
| Q4 25 | $698.6M | $351.2M | ||
| Q3 25 | $702.3M | $333.9M | ||
| Q2 25 | $698.5M | $328.8M | ||
| Q1 25 | $767.9M | $326.9M | ||
| Q4 24 | $710.4M | $326.5M | ||
| Q3 24 | $773.5M | $316.5M | ||
| Q2 24 | $768.5M | $426.6M | ||
| Q1 24 | $680.0M | $421.6M |
| Q4 25 | $913.2M | $441.8M | ||
| Q3 25 | $904.9M | $404.5M | ||
| Q2 25 | $907.4M | $393.7M | ||
| Q1 25 | $966.7M | $390.0M | ||
| Q4 24 | $910.4M | $393.7M | ||
| Q3 24 | $991.1M | $389.6M | ||
| Q2 24 | $964.3M | $624.8M | ||
| Q1 24 | $869.8M | $640.8M |
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.18× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $18.0M |
| Free Cash FlowOCF − Capex | $-61.9M | $5.8M |
| FCF MarginFCF / Revenue | -71.3% | 7.6% |
| Capex IntensityCapex / Revenue | 10.7% | 16.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $26.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $18.0M | ||
| Q3 25 | $-78.7M | $24.7M | ||
| Q2 25 | $-67.4M | $21.4M | ||
| Q1 25 | $-103.7M | $8.8M | ||
| Q4 24 | $-73.3M | $-4.1M | ||
| Q3 24 | $-59.0M | $2.8M | ||
| Q2 24 | $-98.4M | $27.6M | ||
| Q1 24 | $-122.3M | $11.9M |
| Q4 25 | $-61.9M | $5.8M | ||
| Q3 25 | $-89.5M | $12.0M | ||
| Q2 25 | $-74.9M | $9.7M | ||
| Q1 25 | $-109.9M | $-1.2M | ||
| Q4 24 | $-77.5M | $-17.7M | ||
| Q3 24 | $-61.3M | $-6.7M | ||
| Q2 24 | $-98.9M | $21.0M | ||
| Q1 24 | $-126.5M | $-1.9M |
| Q4 25 | -71.3% | 7.6% | ||
| Q3 25 | -132.7% | 17.4% | ||
| Q2 25 | -124.9% | 14.3% | ||
| Q1 25 | -222.8% | -1.8% | ||
| Q4 24 | -105.1% | -30.8% | ||
| Q3 24 | -104.6% | -15.2% | ||
| Q2 24 | -317.9% | 31.4% | ||
| Q1 24 | -17685.3% | -3.9% |
| Q4 25 | 10.7% | 16.3% | ||
| Q3 25 | 16.1% | 18.5% | ||
| Q2 25 | 12.4% | 17.1% | ||
| Q1 25 | 12.6% | 15.5% | ||
| Q4 24 | 5.7% | 23.6% | ||
| Q3 24 | 3.9% | 21.4% | ||
| Q2 24 | 1.4% | 9.9% | ||
| Q1 24 | 583.4% | 28.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.37× | ||
| Q2 25 | — | 2.47× | ||
| Q1 25 | — | 0.88× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.43× | ||
| Q1 24 | — | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
NPKI
| Rental Revenue | $34.8M | 46% |
| Products | $25.5M | 34% |
| Services | $14.9M | 20% |
